Assigning the molecular heterogeneity of gliomas and classifying them into dissimilar clinical groups based on codeletion of chromosome arms 1p/19q, IDH mutations, and telomerase reverse transcriptase (TERT) promoter mutations that are characterized by different mechanisms of pathogenesis is important. Here, IDH1 is linked to central nervous system cancer.